Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial.

摘要: Background New antibacterial agents with activity against pathogenic strains resistant to established antibiotics are needed treat patients secondarily infected dermatitis (SID). Objective We sought determine the clinical safety and efficacy of topical retapamulin ointment 1% versus oral cephalexin for treatment SID. Methods Patients SID were randomly assigned (twice daily [bid]) 5 days, or (500 mg bid) 10 days. The primary end point was response at follow-up. Secondary outcomes included microbiologic at follow-up, safety, compliance. Results Retapamulin as effective (clinical success rates follow-up: 85.9% 89.7%, respectively). Microbiologic follow-up 87.2% 91.8% cephalexin. well tolerated formulation preferred over drug. Limitations An imbalance existed in number outcome "unable determine" (15 retapamulin, 2 cephalexin), mainly because their failure attend study visit. If those who failed visits (who did not withdraw a result drug-related events) removed from analysis, 89.9% 89.7% Conclusions (bid) 5 days in treatment SID, tolerated.